The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
|Articles|April 22, 2022
Daily OTC Pearl: PinkEye Relief
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: PinkEye Relief
Indication: PinkEye Relief are sterile eye drops that temporarily relieve burning, swelling, and crusting.
Insight:
- Non-prescription drug products cannot treat infections.
- Store at room temperature 59 degrees to 86 degrees F (15 degrees to 30 degrees C).
- Keep bottle tightly closed.
- Active ingredients are micro-diluted in accordance with the homeopathic pharmacopoeia of the United States and are therefore non-toxic with no known side effects or contraindications.
- Directions: Squeeze 1-3 drops in the eye. Use several times per day as needed. Suitable for adults and children 2 years of age and over.
- For children under the age of 2, consult a physician before use. Homeopathic remedies may not be effective for everyone. Individual results may vary.
Source:
Advertisement
Related to this article
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5